168123-82-8

Basic information

• Product Name: 7-BROMOPYRIDO[2,3-B]PYRAZINE-2,3(1H,4H)-DIONE
• Synonyms: 7-Bromo-2,3-dioxo-1,4-dihydro-pyrido[2,3-b]pyrazine;7-broMo-1H,2H,3H,4H-pyrido[2,3-b]pyrazine-2,3-dione;7-BROMOPYRIDO[2,3-B]PYRAZINE-2,3(1H,4H)-DIONE;7-bromo-1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione
• CAS NO: 168123-82-8
• Molecular Formula: C7H2BrN3O2
• Molecular Weight: 240.01
• Mol File: 168123-82-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 527 °C at 760 mmHg
• Flash Point: 272.5 °C
• Appearance: /
• Density: 1.851 g/cm³
• Vapor Pressure: 1E-11mmHg at 25°C
• Refractive Index: 1.63
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-BROMOPYRIDO[2,3-B]PYRAZINE-2,3(1H,4H)-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BROMOPYRIDO[2,3-B]PYRAZINE-2,3(1H,4H)-DIONE(168123-82-8)
• EPA Substance Registry System: 7-BROMOPYRIDO[2,3-B]PYRAZINE-2,3(1H,4H)-DIONE(168123-82-8)

Safety Data

• Hazardous Substances Data: 168123-82-8(Hazardous Substances Data)

Usage

General Description

7-Bromopyrido[2,3-b]pyrazine-2,3(1H,4H)-dione is a chemical compound with the molecular formula C8H4BrN3O2. It is a heterocyclic compound containing a pyrido[2,3-b]pyrazine ring system with a bromine substituent and a dione functional group. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 7-BROMOPYRIDO[2,3-B]PYRAZINE-2,3(1H,4H)-DIONE has potential applications in the pharmaceutical industry due to its ability to act as an effective building block in the synthesis of various biologically active compounds. Additionally, 7-Bromopyrido[2,3-b]pyrazine-2,3(1H,4H)-dione is also used as a reagent in organic chemical reactions and as a research tool in the study of heterocyclic chemistry.

InChI:InChI=1/C7H4BrN3O2/c8-3-1-4-5(9-2-3)11-7(13)6(12)10-4/h1-2H,(H,10,12)(H,9,11,13)

Upstream product

• 38875-53-5 5-bromo-pyridine-2,3-diamine 
• 144-62-7 oxalic acid 
• 6945-68-2 5-bromo-3-nitro-pyridin-2-ylamine 
• 95-92-1 oxalic acid diethyl ester 

Relevant articles and documents

Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis

The histamine H4 receptor (H4R), a member of the G-protein coupled receptor family, has been considered as a potential therapeutic target for treating atopic dermatitis (AD). A large number of H4R antagonists have been disclosed, but no efficient agents controlling both pruritus and inflammation in AD have been developed yet. Here, we have discovered a novel class of orally available H4R antagonists showing strong anti-itching and anti-inflammation activity as well as excellent selectivity against off-targets. A pharmacophore-based virtual screening system constructed in-house successfully identified initial hit compound 9, and the subsequent homology model-guided optimization efficiently led us to discover pyrido[2,3-e]tetrazolo[1,5-a]pyrazine analogue 48 as a novel chemotype of a potent and highly selective H4R antagonist. Importantly, orally administered compound 48 exhibits remarkable efficacy on antipruritus and anti-inflammation with a favorable pharmacokinetic (PK) profile in several mouse models of AD. Thus, these data strongly suggest that our compound 48 is a promising clinical candidate for treatment of AD.

Discovery and analgesic evaluation of 8-chloro-1,4-dihydropyrido[2,3- b ]pyrazine-2,3-dione as a novel potent d -amino acid oxidase inhibitor

A series of 5-azaquinoxaline-2,3-dione derivatives were synthesized and evaluated on d-amino acid oxidase (DAAO) inhibition as potential α-hydroxylactam-based inhibitors. The potent inhibitory activities in vitro suggested that 5-nitrogen could significantly enhance the binding affinity by strengthening relevant hydrogen bond interactions. The analgesic effects of intrathecal and systemic injection of 8-chloro-1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione, a representative molecule of 5-azaquinoxaline-2,3-dione, were investigated in rodents. This research not only confirmed the analgesic effect of the DAAO inhibitors but provided a new class of chemical entities with oral application potential for the treatment of chronic pain and morphine analgesic tolerance.

8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor

Disclosed is a method of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma or hypoglycemia. The method comprises administering to an animal a compound of the formula: STR1 or a pharmaceutically acceptable salt thereof; wherein n is zero or 1; R 4, R 5, R 6 are independently hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, cycloalkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy, or haloalkoxy; and R c and R d are defined in the specification. These compounds have high binding to the glycine site of the NMDA receptor.